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Edited by Jesus AvilaAbstract Mild to moderate hyperhomocysteinemia is a risk
factor for neurodegenerative diseases. Human studies suggest
that homocysteine (Hcy) plays a role in brain damage, cognitive
and memory decline. Numerous studies in recent years investi-
gated the role of Hcy as a cause of brain damage. Hcy itself
or folate and vitamin B12 deﬁciency can cause disturbed methyl-
ation and/or redox potentials, thus promoting calcium inﬂux,
amyloid and tau protein accumulation, apoptosis, and neuronal
death. The Hcy eﬀect may also be mediated by activating the
N-methyl-D-aspartate receptor subtype. Numerous neurotoxic
eﬀects of Hcy can be blocked by folate, glutamate receptor
antagonists, or various antioxidants. This review describes the
most important mechanisms of Hcy neurotoxicity and pharma-
cological agents known to reverse Hcy eﬀects.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The role of micronutrients in neuronal development and
degeneration has been established [1–4]. Homocysteine (Hcy)
is a non-essential sulfur-containing amino acid that is derived
from methionine metabolism. Hcy catabolism depends on
folate, vitamin B12, and vitamin B6. Therefore, plasma
concentration of Hcy may indicate the nutritional status of
the B-vitamins [5]. The role of folate in neurolation during
early embryonic life has been well documented. Hcy delays
the closure of the neural tube in chick embryo by inhibiting
the transmethylation pathway [6]. This data has been sup-
ported by the eﬀect of folate supplementation in preventing
neural tube defects. Deﬁciency of one of the cofactors in
Hcy metabolism can cause impaired myelination and severe
neurological damage. A link between Hcy and disorders in
the nervous system was ﬁrst documented in patients with se-Abbreviations: Hcy, homocysteine; HHCY, hyperhomocysteinemia;
AD, Alzheimer disease; Ab, amyloid beta; SAH, S-adenosyl homo-
cysteine; SAM, S-adenosyl methionine
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doi:10.1016/j.febslet.2006.04.088vere cystathionine beta synthase (CBS) deﬁciency [7,8]. Mental
retardation, cerebral atrophy, and seizures have been reported
in such patients [7–10].
The remethylation of Hcy into methionine is mediated by
methionine synthase and its cofactor vitamin B12. 5-Methyl-
tetrahydrofolate donates a methyl group in this reaction.
Hcy remethylation is an important source of methyl groups
in the brain [11]. Numerous methylation reactions take place
in the brain including synthesis and degradation of neurotrans-
mitters, membrane phospholipids and controlled DNA-meth-
ylation. The alternative remethylation pathway of Hcy via
betaine-homocysteine methyl transferase seems to be absent
in the brain (Fig. 1) [12,13].
The homocysteine transsulfuration pathway is important for
Hcy catabolism and is considered a major source of glutathi-
one in the liver. The situation in the brain however, is less
clear. Cystathionine beta synthase and cystathionase catalyze
the transsulfuration of Hcy into cysteine, the precursor of glu-
tathione. The enzyme CBS has been detected in the human
brain [14]. Data about cystathionase in the brain has not been
consistent [15–17]. Moreover, there have been few studies that
showed large regional variations in cystathionase activity in
the brain [16,17]. Moreover, cysteine and, to a lesser degree
cystathionine, were utilized by astroglial culture to produce
glutathione [18]. In contrast, Hcy and methionine were not
able to pass the transsulfuration pathway to be converted into
glutathione in astroglial culture [18].
In general, available data does not support a major role for
Hcy transsulfuration in the production of cysteine necessary
for glutathione synthesis in the brain [11,18,19]. Cysteine is
the rate-limiting substrate for the synthesis of glutathione
[19,20], which has been shown to be transported via a Na-
dependent glutamate transporter in astrocytes [19]. It is likely
that cysteine precursors (cystathionine, homocysteine, and
methionine) may have a major role for maintaining brain glu-
tathione by maintaining blood cysteine. However, studies are
still needed to clarify this view.
Homocysteine transport in the brain has not been fully ex-
plored. Early animal studies indicated that Hcy can be trans-
ported via a speciﬁc saturable receptor in addition to simple
diﬀusion [21–23]. Human neuronal cells are capable of produc-
ing Hcy under normal conditions [24]. An increased produc-
tion of Hcy has been documented in neuronal cells incubated
in folate deﬁcient media [24]. These results demonstrated that
Hcy can be produced within the brain itself. Regional varia-
tions in Hcy metabolism within the brain have not been inves-blished by Elsevier B.V. All rights reserved.
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Fig. 1. Homocysteine metabolism. SAM, S-adenosyl methionine; SAH, S-adenosylhomocysteine; HCY, homocysteine; Met, methionine; Gly,
glycine; THF, tetrahydrofolate; MTHF, 5-methlytetrahydrofolate; GSH, glutathione.
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integrity of the blood–brain barrier in a mice model of hype-
rhomocysteinemia (HHCY) [25]. However, the research done
on the ability of Hcy to enter the brain via the blood–brain
barrier and the eﬀect of secondary HHCY (renal patients) on
brain Hcy has not been suﬃcient. Current evidence suggests
that Hcy can be imported from the plasma into the brain
and vice versa probably via speciﬁc, bi-directional cellular
transporters [21].
Concentrations of Hcy in the brain and cerebrospinal ﬂuid
(CSF) are elevated in several neurological diseases [26–30]. Ele-
vation of Hcy in the CSF parallels that in serum; however ser-
um concentrations are 20–100-fold higher than concentrations
in the CSF. Antifolate treatment (methotrexate) lowered con-
centrations of folate and S-adenosyl methionine (SAM) and
increased Hcy in serial CSF samples [31]. This indicates that
a methotrexate neurotoxic eﬀect might be explained by folate
depletion and/or increased Hcy in the brain. Furthermore, se-
vere HHCY (>100 lM) in children with CBS deﬁciency was
associated with a 10-fold increase in concentrations of Hcy
in CSF [32]. Treating homocystinuric patients with betaine
lowered concentrations of Hcy in their plasma and CSF [32].
This data suggests that Hcy may cross the blood–brain barrier
probably in both directions. The ﬁnding that Hcy compro-
mises the integrity of the blood–brain barrier provided further
support to this view [25].2. Homocysteine is linked to neurodegenerative diseases and
aging
Neurodegenerative diseases include a wide group of disor-
ders of various ethologies and clinical features. These diseases
share one important feature; that is a disorder in protein struc-ture which can cause deterioration of certain nerve cells or neu-
rons. Dementia, Alzheimer’s disease (AD), Parkinson‘s disease
and stroke are examples of neurodegenerative diseases that are
common in elderly people. Mild cognitive impairment is a ma-
jor health problem in elderly people that will progress into
dementia in about 50% of the cases [33]. AD is a multifactorial
disease that is related to both genetic and acquired factors. The
pathological hallmark of AD is the accumulation of neuroﬁ-
brillary tangles, neuritic plaques, and the insoluble amyloid
beta (Ab) [34,35]. This process occurs 10–20 years before the
cognitive decline [36]. Pathological mechanisms involved in
neurodegenerative diseases include apoptosis, neuronal death,
oxidative stress, overactivation of glutamate receptors, mito-
chondrial dysfunctions and activation of caspases [37–39].
Brains of patients with AD showed abnormal redox balance
and oxidative damage to proteins, and nucleic acids [40,41].
Hcy promotes neuronal degeneration and thus it contributes
to psychiatric and age-related neurodegenerative diseases. In
the general population, the interest regarding Hcy metabolism
in relation to neurodegenerative diseases arises from the fact
that plasma concentration of Hcy increases with age [5,42].
Hcy has been implicated as a risk factor for vascular disease
as well as brain atrophy [43]. Concentrations of Hcy above
11.9 lmol/L were associated with approximately 3-fold higher
risk for white matter damage when compared to concentra-
tions below 8.6 lmol/L [44]. Epidemiological and longitudinal
studies suggested a causal link between Hcy and cognitive
impairment [45]. This may be due to cerebrovascular as well
as to direct neurotoxic mechanisms [46]. Changes of Hcy over-
time predicted the decline in memory scores in elderly subjects
who were followed for a mean of 6 years [45]. Several follow up
studies demonstrated a positive association between Hcy at
baseline and a worsening in some measures of cognitive func-
tion after several years [47–49].
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malonic acid (MMA >271 nmol/L) (a functional metabolic
marker for vitamin B12 deﬁciency) are common in the neuro-
psychiatric population in the absence of haematological man-
ifestations [50]. Numerous studies have conﬁrmed that low
concentrations of folate, vitamin B12, and/or B6 are common
in demented elderly persons. Serum concentrations of B-vita-
mins were negatively related to deﬁcits in neurocognitive tests
[4]. Moreover, concentrations of Hcy were a stronger predictor
of cognitive decline than low vitamin concentrations [51]. Nev-
ertheless, it remains unclear whether Hcy causes dementia, or
if it is a surrogate marker for folate or B12 deﬁciencies, and
disturbed transmethylation reactions in the brain.
Despite the fact that in vitro and in vivo studies strongly sug-
gested a causal role for Hcy in the neurological diseases, clinical
studies were not conclusive. The association between HHCY
(Hcy >12.0 or 15.0 lmol/L) and cognitive decline, dementia
or AD was positive in the majority of retrospective and pro-
spective studies [47–49]. However, a causal role can only be
conﬁrmed by vitamin supplementation studies. Two issues to
be considered in these studies are; ﬁrst HHCY is one of several
other factors that may enhance the total risk. Second, in
chronic conditions such as AD, or following acute lesions such
as stroke, neurons will degenerate and lost neurons or axons
will not be replaced. This may explain that vitamin supplemen-
tation did not improve cognitive function in elderly patients
with vascular lesions [52]. The role of Hcy as an independent
risk factor for stroke has been conﬁrmed by many investigators
and recent data demonstrated an improvement in stroke mor-
tality in Canada and the United States after folate fortiﬁcations
[53]. Large scale-controlled studies are needed before a deﬁnite
conclusion can be drawn. In general, it seems that vitamin sup-
plementation or higher intake should be initiated at an earlier
age, before the clinical onset of dementia.3. Mechanisms of homocysteine toxicity in the central nervous
system
Hcy is toxic to neuronal cells [54–56]. Neurological damage
has been reported in mice deﬁcient in CBS enzyme (Cbs /+ or
Cbs /), where Hcy increased by approximately 2–50-fold in
comparison to wild type mice, depending on the genotype and
the type of diet [25,57,58]. These animals show alterations in
neuronal plasticity, suﬀer from severe retardation and die early
[59]. Animals exposed to Hcy accumulate this compound in the
brain [60], suﬀer from restricted growth, neural or cognitive
dysfunction [60,61], and impaired brain energy metabolism
[62]. Moreover, HHCY has been implicated in neural plasticity
and neurodegenerative disorders in human studies [63]. This
review summarizes the role of Hcy as a neuronal toxin in rela-
tion to other biological mechanisms in dementia (Table 1).
3.1. Homocysteine and glutamate receptors
Hcy is an endogenous glutamate receptor agonist [54,64–66]
that is prone to act on N-methyl-D-aspartate (NMDA) recep-
tor subtype [54,67]. Homocysteic acid, an oxidative product of
Hcy, is produced by brain cells and released in response to
excitatory stimulation [68]. Homocysteic acid functions as an
excitatory neurotransmitter by activating NMDA receptor
[69]. The neurotoxicity of homocysteic acid in the brain can
be blocked by using a selective NMDA antagonist [66,70].By binding to NMDA receptor [23], Hcy indirectly enhances
calcium inﬂux [54,56,70,71]. Interestingly, in the presence of
low (i.e., normal; 10 lmol/L) concentrations of glycine, Hcy
acts as a partial antagonist of the glycine site of the NMDA
receptor, and inhibits receptor-mediated activity (Hcy role as
antagonist or neuroprotective) [54]. The toxicity of Hcy in
the presence of normal glycine may be observed when Hcy is
at high concentrations (i.e., Hcy = 100 lmol/L). In contrast,
when glycine levels increase in the nervous system (after stroke,
head trauma, or migraine) [72], a relatively low concentration
of Hcy (i.e., Hcy = 10 lmol/L) can be excitotoxic (agonist) by
binding and activating NMDA [54,73,74]. These results have
suggested that Hcy may contribute to cerebral damage in pa-
tients with migraine, after stroke or after ischemia [54]. There-
fore, depending on glycine concentrations, Hcy may either
block the glycine site of the NMDA receptor or may act as
an antagonist at the glutamate site of this receptor [54].
An another line of evidence suggested that Hcy can act via a
non-NMDA receptor mechanism or by activating the group I
metabotrophic glutamate receptor [73]. Hcy has been shown to
induce an extra-cellular signal regulated kinase in the hippo-
campus. This eﬀect was blocked by three types of glutamate
receptor antagonists (NMDA, non-NMDA, and metabo-
trophic glutamate receptor) [71]. By activating ionotrophic
and metabotrophic receptors, Hcy may indirectly increase
intracellular calcium levels and activate several kinases [71].
3.2. Homocysteine and oxidative stress
Hcy metabolism is regulated by the redox potential in the
cell [75,76]. The activities of several enzymes that mediate the
clearance of Hcy are regulated by this oxidative status (i.e.,
methionine synthase, CBS) [75,77,78]. For example, the activ-
ity of CBS is increases under conditions of oxidative stress,
thus converting more Hcy into cysteine and glutathione. Dis-
ruption of the transsulfuration pathway (Cbs +/) disturbs re-
dox homeostasis and reduces cysteine levels [57], thus
contributing to neuronal damage. In contrast, the activity of
methionine synthase is lower in the case of increased reactive
oxygen species (ROS). Rats fed a methionine rich diet showed
elevated concentrations of Hcy in blood (20 vs. 7 lM in the
control rats) and a lowered activity of glutathione peroxidase
[79]. Hcy-induced oxidative stress may be worsened in case
of a reduced glutathione production.
Hcy itself can undergo autooxidation, thus causing the dis-
ruption of redox homeostasis and aﬀecting the redox signaling
pathways in vascular and neuronal cells [75,80,81]. Hcy has
been found to induce neurological dysfunction via oxidative
stress [82,83]. This eﬀect can be explained by enhancing the
production of ROS, and oxidative deactivation of nitric oxide.
Moreover, Hcy causes brain lipid peroxidation by blocking
NMDA receptor [84]. Antioxidant treatment restores several
toxic eﬀects of Hcy [84].
The role of oxidative stress in neurodegeneration has been
intensively studied. Oxidative stress was one important mech-
anism for Hcy toxicity in neuronal cells [85]. Hcy directly in-
creased the neurotoxicity of Ab by inducing oxidative stress
[83]. The cytotoxicity of Hcy was mitigated by antioxidants
like N-acetyl cysteine, vitamin E or C [83,86,87]. Antioxidants
(vitamin E or C) also prevented memory dysfunction [86] and
ATPase activity caused by Hcy in rats [87]. Other studies
showed an eﬀect of folate deﬁciency on the CNS [85,88]. Folate
deprivation induced a marked increase in Hcy and ROS and
Table 1
Summary of some studies testing the neurotoxic eﬀects of HHCY or vitamin deﬁciency
Authors Model › Hcy or ﬂ B-vitamins Mechanisms Neuroprotective agent
Ho et al. [85] SH-SY-5Y
neuroblastoma
Folate free medium › Hcy in the medium DZA (SAH-hydrolase
inhibitor), NMDA
antagonistHuman primary cortical
neurons
› Cytosolic Ca2+
› Ab
› Oxidative stress
› P-tau
› Apoptosis
Ho et al. [85] Hcy 10–250 lM › Calcium inﬂux NMDA antagonist
Parsone et al. [55] Neuroblastoma
SK.N.SH
Hcy 0–200 lM › Cell death
Medulloblastoma TE
671
Glioblastoma U-87 MG
Robert et al. [71] Cbs / and Cbs +/+
mice
Blood Hcy  50 fold
higher in Cbs / mice
› Calcium inﬂux NMDA antagonist,
Na+-channel blocker,
NMDA antagonistBrain Hcy 1.7 vs.
0.2 lM/mg cell proteins
› ERK 1/2 activation
Robert et al. [71] Mouse hippocampal
slices
Hcy 100 and 200 lM for
10–30 min
Hcy as a glutamate
agonist (NMDA and
non-NMDA receptors)
Hasegawa et al. [121] Primary rat cortical
neurons
HA 10 nM to 100 lM ﬂ Extracellular Ab42 c-Secretase inhibitor
Hcy 10–100 lM › Intracellular Ab42
Vitvitsky et al. [57] Cbs +/ and Cbs +/+
mice: control
Mean Hcy 10.6 vs.
5.7 lM
ﬂ Brain CBS activity –
diet/›Met ﬂ folate diet Mean Hcy 64.5 vs.
21.4 lM
ﬂ Brain cystein
Cbs / mice ﬂ Brain glutathione
Lipton et al. [54] Primary rat cortical
cultures, mixed neurons/
Glia
Hcy = 5 mM › Calcium inﬂux NMDA antagonists,
Catalase, SOD,
Memantin
Hcy = 100–150 lM and
Glycine = 10 lM
Hcy = 100–150 lM and
Glycine = 50 lM
Kruman et al. [56] Primary rat
hippocampal cells
Hcy 0.5–250 lM › Apoptosis and necrosis Poly-ADP-ribose
at Hcy 250 lM; Polymerase inhibitors
› DNA-damage
› Poly-ADP-ribose
polymerase
› Caspase-3 activity
› P53 immunoactivity
› Oxidative stress
›Mitochondrial ROS
Lee et al. [141] Rats control diet; 3 g/kg
Hcy for 3 week; then
folate 8 mg/kg for 8 week
Plasma Hcy increased by
400% at 10 week in
comparison to animals
on the control diet
› Damaged vessels Folate
ﬂ Expression of glucose
transporter-1 in the
brain
Baydas et al. [79] Rats fed a control diet or
a diet rich of Met
Plasma Hcy was 20 vs.
7 lM in the Met group
versus the control diet
› Lipid peroxidation Melatonin;
ﬂ Glutathione
peroxidase
lowered Hcy
ﬂ Neuronal cell adhesion
molecule
Lowered lipid
peroxidation
Impaired learning and
memory performance
increased neuronal cell
adhesion molecule
Baydas et al. [145] Rat hippocampus Diet (Met) induced
HHCY
Oxidative stress Melatonin
Caspase 3 activation
Cytochrome C
translocation
(continued on next page)
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Table 1 (continued)
Authors Model ›Hcy or ﬂ B-vitamins Mechanisms Neuroprotective agent
Tjiattas et al. [146] Chicks primary neuronal
cells
Folate deﬁcient media
for 2 h or Hcy 250 lM
for 2 h
› cytosolic Ca2+ DZA (SAH-hydrolase
inhibitor),
› Oxidative stress NMDA antagonists,
ﬂMitochondrial
membrane potential
Inhibitors of Ca2+ eﬄux
Jara-Prado et al. [84] Rat brain synaptosomes Hcy 5–1000 lM › Brain lipid
peroxidation
NMDA receptor
antagonists,
› NMDA receptor
stimulation
N-acetyl cysteine, Non-
speciﬁc NOS inhibitors
› NOS activation
Pacheco-Quinto et al. [147] Cbs /+; APP; PS1 mice Hcy = 7.9 vs. 12 lM in
Cbs +/+ vs. Cbs /+
› Brain Ab-40 and Ab-
42
–
Shea et al. [107] ApoE deﬁcient and
normal mice
Folate supplemented or
Folate deﬁcient diet
Oxidative stress in the
brain
Folate and vitamin E
Iron induced oxidative
stress
Fuso et al. [112] Human neuroblastoma Folate and B12 deﬁcient
media
Hypomethylation of nt
451–454 in the promoter
region of PS1
SAM
Algaidi et al. [60] Rats Chronic Hcy injection Spatial reference
memory learning
–
Christie et al. [148] Rats Chronic Hcy injection
for 4 weeks
hippocampal plasticity
and a slow-onset
disruption in synaptic
transmission
–
Lee et al. [149] Rat brain Diet containing 0.3%
Hcy
ﬂ Cerebrovascular eNOS
activity
Dietary folate
ﬂ Glucose Transporter-1
› VCAM-1
Kamath et al. [25] CBS +/ mice Vitamin deﬁcient
methionin rich diet for 8
weeks
Damage to the blood–
brain barrier
–
Hcy, homocysteine; Met, methionine; Cbs, cystathionine beta synthase; APP, amyloid precursor protein; PS1, Presenilin 1; Ab, amyloid beta; DZA,
3-diazaadenosine; SOD, superoxidedismutase; NOS, nitric oxide synthase.
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prevented the generation of ROS by Ab [85]. Treatment with
the S-adenosyl hydrolase inhibitor, 3-deaza adenosine, pro-
vides neuroprotection in normal and apolipoprotein E-deﬁ-
cient mice and in cultured neuronal cells deprived of folate
and vitamin E and subjected to oxidative challenge [89]. It is
however, not known whether the eﬀect of folate deﬁciency
on the brain is independent on or mediated by Hcy elevation.
The transsulfuration pathway represents the metabolic link
between antioxidant and methylation metabolism [90]. There
is evidence suggesting an antioxidant role for SAM. SAM
caused increased glutathione production, lowered lipid perox-
idation by almost 65% [91] and prevented neuronal death in an
experimental model of ischemia (oxidative stress) [92]. In vivo
studies were able to demonstrate an improvement in the
blood–brain barrier after transient cerebral ischemia in the
presence of SAM [93]. Moreover, chronic SAM treatment
(22 months) increased concentrations of glutathione and low-
ered lipid peroxidation in rat brain [94]. More evidence has
been provided by clinical studies where B-vitamins mitigate
oxidative damage when administered immediately after acute
ischemic stroke [95]. At least some of the neuroprotective ef-
fects of SAM can be related to its important role in enhancingthe transsulfuration pathway and increasing the production of
glutathione.
A new and interesting link has been recently reported be-
tween folate deﬁciency and lowered melatonin production
[96]. Melatonin is an indole hormone that is produced in the
pineal gland from serotonin via a methyltransferase enzyme
(hydroxyl-indole-O-methyltransferase) that utilizes SAM as a
methyl donor. Melatonin regulates circadian rhythm and has
a signiﬁcant neuroprotective role that is mostly related to its
antioxidant eﬀects [97]. Melatonin can directly scavenge free
radicals [98,99] and can increase the expression and activities
of several antioxidant enzymes [100]. Melatonin prevents oxi-
dative stress and death of neurons exposed to Ab [101,102].
Recent studies showed that melatonin protects against the
neurotoxicity of Hcy by mechanisms related to its antioxidant
eﬀects and its ability to modulate apoptosis [79,103]. Oxidative
stress and the accumulation of oxidatively damaged proteins
increase with age and age-related pathologies. On the other
hand, aging is also associated with increased plasma concen-
trations of Hcy [5,104] and its oxidized form, homocysteic
acid. Careful review of the literature suggests that melatonin
is probably not eﬀective in managing the cognitive manifesta-
tions of dementia [105]. However, melatonin lowered Ab in
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accumulation is probably not reversible later in life.
AnothermechanismbywhichHcy-associated-oxidative stress
can cause neuronal damage, is increased hyperphosphorylated
tau (P-tau) protein (discussed below). B-vitamins have been
found tomodulate the impact of genetic factors on neurodegen-
eration. In accordance with this, ApoE knockoutmice exhibited
increased brain oxidative damage and cognitive deﬁcits when
theywere folate deﬁcient [107,108]. Thismay imply that patients
with certain risk factors (i.e., ApoE4, APP)may bemore suscep-
tible to oxidative stress caused by folate deﬁciency.
3.3. Homocysteine and hypomethylation
HHCY, folate or vitamin B12 deﬁciency can cause lowered
SAM and elevated S-adenosyl homocysteine (SAH), the po-
tent competitive inhibitor for methyltransferases. Experimen-
tal hyperhomocystemia led to increased concentrations of
Hcy and SAH in the brain [109]. The importance of methyla-
tion for the CNS has been reviewed elsewhere [63]. Synthesis
and catabolism of several neurotransmitters as well as main-
taining DNA-methylation are all important biological reac-
tions where the methyl groups are required.
Folate or vitamin B12 deﬁciency can cause decreased SAM.
On the other hand, increased concentration of Hcy is associated
with increased production of SAH via the reversible reaction
mediated by SAH-hydrolase. A lower ratio of SAM/SAHcauses
DNA damage and thereby apoptosis, which is one important
explanation for Hcy neurotoxicity [56]. In accordance with this,
SAM reduced apoptosis (by 50%) that is caused by Hcy in cor-
tical neuronal cells [110]. Supplementing SAM after ischemia
improves the blood–brain barrier and neuronal survival [93]
and protects against disturbances in brain phospholipids [111].
Hcy can increase neuronal death and DNA damage [56].
Hypomethylation of DNA and altered gene expression are
two important mechanisms leading to neuronal damage caused
by elevated Hcy. Deﬁciency of folate or vitamin B12 caused low
SAM and DNA-hypomethylation in cultured neuroblastoma
cells, an eﬀect mitigated by SAM [112]. Presenilin 1 (PS1) gene
expression is one important example that has been tested in rela-
tion to methylation [112–114]. PS1 is a c-secretase that mediates
the formation of Ab from amyloid precursor protein (APP)
[112]. DNA hypomethylation causes accelerated APP process-
ing and Ab production through the upregulation of the PS1
gene. Moreover, exogenous SAM can silence the PS1 gene thus
reducingAbproduction. Silencing thePS1gene couldbe a target
therapy for AD patients [113,114]. These results suggest that
treating folate and vitamin B12 deﬁciency can protect against
Ab accumulation in dementia by supplying methyl groups.
Another important biological reaction where hypomethyla-
tion can increase brain damage in AD is the dephosphoryla-
tion of P-tau protein. The enzyme protein phosphatase 1
(PPM1) is involved in the regulation of protein phosphatase
2A, the enzyme that dephosphorylate tau protein [115]. The
methylation by PPM1 is SAM-dependent; hence reduced
methylation capacity can increase P-tau (discussed below).
3.4. Homocysteine, tau protein and amyloid beta
Extensive Ab deposition in the brain increases as a part of
the normal aging process. A prominent feature of the AD
brain is the widespread cerebral deposition of Ab within senile
plaques and in cerebral and meningeal blood vessel [116,117].
Concentrations of Ab are low in CSF samples from AD pa-tients and vascular dementia, and this decrease is related to
cognitive decline.
A positive association between plasma concentrations of Hcy
and that of Ab1–40 has been recently reported in aging and neu-
rodegenerative disease [118]. A homocysteine-responsive endo-
plasmic reticulum protein (Herp) has been recently identiﬁed
and found to enhance the c-secretase activity and thereby
Ab1–40 accumulation in the brain [119]. On the other hand,
Hcy can be toxic to neurons and can increase their vulnerability
to being damaged by Ab [83,120]. Homocysteic acid results
in the accumulation of intracellular and extracellular Ab 42 in
neuronal cells [121]. In vascular smooth muscle cells, Hcy in-
creased Ab toxicity and caspase-3 activation in a dose depen-
dent manner [122]. To sum up, current data suggests that Hcy
accelerates dementia by stimulating Ab deposition in the brain.
Tau protein is another important protein in the human brain
that has been implicated inmemory decline anddementia. Tau is
an intracellularmicrotubule-associated protein that participates
in forming the neuroﬁbrillary tangles (NFTs). NFTs correlate
with cognitive deﬁcits, neurodegenerative disorders and demen-
tia. The physiological function of tau is to facilitate tubulin
assembly and to stabilize microtubules. Tau phosphorylation
seems to inﬂuence its distribution and can modulate its associa-
tion with plasma membrane. Increased hyperphosphorylated
tau (P-tau) may be related to a lower phosphatase activity or
to an increased kinases activity (Fig. 2). IncreasedAbmay accel-
erate tau accumulation by activating the kinases that phosphor-
ylate tau (GSK3beta, phosphatidylinositol 3-kinase (PI3K),
MAP kinase) [123]. The enzyme protein phosphatase 2A
(PP2A) can dephosphorylate P-tau in paired helical ﬁlaments,
making tau detached and accessible to proteolysis [124]. Factors
that inﬂuence the activity of kinases (decrease) or phosphatases
(increase) may therefore hold a therapeutic potential for AD.
Several studies have shown that the expression or the activ-
ity of PP2A was reduced in brain tissues from AD patients in
comparison to controls [125,126]. The expression of the PP2A
protein was also low in ﬁbroblasts from AD patients [127]
although mRNA PP2A was increased. These results suggest
a failure in post-translational modiﬁcations or in the stability
of the enzyme.
A possible link between AD and reduced PP2A protein
methylation in hyperhomocysteinemia has been hypothesized
[128]. The attachment of the catalytic subunit B to the methyl-
ated subunit C of the enzyme is essential for the activity of the
enzyme [129]. Low concentrations of SAM or a low SAM/
SAH ratio results in a lower activity of PP2A and increased
P-tau [128,130]. Accordingly, the protein level of phosphatase
methyltransferase 1, and that of the methylated C subunit of
PP2A were approximately 40% lower in frontal and temporal
extracts from AD patients in comparison to that of the con-
trols [126]. In addition, PP2A protein activity and gene expres-
sion were markedly reduced in the brains of AD patients [125].
As a whole, this data strongly suggests that alterations in
SAM-metabolism or SAM/SAH ratio may contribute to the
ethiology of AD by inhibiting dephosphorylation of tau.
Experimental folate deﬁciency in neuronal cells has provided
additional evidence. Folate deprivation in neuroblastoma cells,
induced a marked elevation in Hcy level and ROS, in addition
to an increase in the immunoreactivity of P-tau by 66% [85].
The increment of P-tau was reversible after adding folate to
the cultures [85]. These results suggested that P-tau accumu-
lates in folate deﬁciency, but this phenotype is probably revers-
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Fig. 2. The role of SAM, and Hcy in phospho-tau and amyloid beta metabolism. PP2A, protein phosphatase 2A; Tau-p, phosphorylated tau; PS,
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might lead to improved memory function [131], Hcy-lowering
treatment may improve memory function via reducing P-tau.
3.5. Miscellaneous
Oxidativemodiﬁcationsof thiol residues in functional proteins
predispose these molecules to homocysteinylation [132–134]
thereby causing structural and functional disruptions.Homocys-
teine thiolactone is a highly active thioester that is formed by an
enzymatic conversion of Hcy in error editing aminoacyl-tRNA
[135]. Homocysteine thiolactone can react with some cellular
molecules and modify their structure and functions [136,137].
Possible structural modiﬁcations of some functional proteins
by Hcy in the central nervous system have not been tested.
Hyperhomocysteinmeia is associated with increased plasma
concentrations of asymmetric dimethylarginine (ADMA), a
potent endogenous inhibitor of nitric oxide (NO)-synthase. A
recent study suggested that Ab enhances the production of
NO and mitochondrial dysfunction as well as apoptosis
[138]. NO plays a signiﬁcant role in mediating neuronal death.
Therefore, ADMA may play a role in brain aging and Alzhei-
mer’s disease by regulating NO synthesis [139]. However, this
data was not conﬁrmed by all studies [140].
Homocysteine has been linked to vascular damage. This ef-
fect could be related to lowering the bio-availability of endothe-
lial NO which is a potent vasodilator. This is in agreement with
the ﬁnding that folate supplementation in animals can reduce
the endothelial damage in brain microvasculator [141].
Mild to moderate HHCY can be a secondary manifestation
in patients with Parkinson disease treated with L-dopa [142].
Increased concentrations of Hcy in those patients can be
explained by O-methylation of L-dopa by the enzyme cate-chol-O-methyltransferase, a SAM-dependent enzyme, that is
up-regulated in L-dopa treated patients [143]. Although
HHCY can be a secondary manifestation in patients with Par-
kinson disease, it is thought to be a risk factor for vascular dis-
eases and cognitive impairment or dementia in those patients.
Vitamin treatment lowered plasma concentrations of Hcy by
about 40% in L-dopa treated patients and this treatment could
be preventive in those patients [142].
Other mechanisms that have been reported are; impairment
of brain energy metabolism and the inhibition of Na+, K+-
ATPase activity caused by the accumulation of the metabolites
in patients with homocysteinuria [62,144].
After reviewing the current literature, a few critical points
should be considered. First, most studies that have been
conducted on cultured neuronal cells have utilized supraphysi-
ological concentrations of Hcy (Table 1) which may not resem-
ble the situation even in HHCY subjects. Second, because Hcy
is an intracellular product, and cells incubated with high con-
centrations of Hcy may incorporate only a limited amount of
that added to the culture, results from various studies can not
be generalized to the case of HHCY patients. Third, most ani-
mal based studies have used dietary manipulations or geneti-
cally modiﬁed animals. Metabolic and genetic diﬀerences
between human and rodents may limit the extrapolation of
the data between these two species. Other critical points in
using mice models of HHCY have been reviewed elsewhere [58].4. Summary and conclusions
Mild to moderate hyperhomocysteinemia (Hcy 15–50 lmol/
L) is an established risk factor for neurodegenerative diseases.
R. Obeid, W. Herrmann / FEBS Letters 580 (2006) 2994–3005 3001HHCY (Hcy 15–50 lmol/L) can be acquired in the case of
cofactor deﬁciency (vitamin B12, B6, and folate), increased
requirements of the vitamins, certain medications, or diseases
(i.e., renal failure). Inherited genetic disorders related to Hcy
metabolism, folate and vitamin B12 transport or metabolism
cause more severe HHCY (Hcy = 70 –100 lmol/L) (methio-
nine synthase, CBS, or transcobalamin deﬁciency). Various
Hcy lowering treatments have been tested and clinical
improvements have been documented, especially in cases
where the intervention started at an early stage of the disease.
A causal link between HHCY and disorders in the central
nervous system has been suggested. However, available results
from treatment studies are very limited. Large controlled stud-
ies are required. Nevertheless, by rationalizing the available re-
sults, prevention seems more feasible than treatment and early
intervention seems crucial in order to achieve a signiﬁcant
eﬀect. Therefore, increasing vitamin intake in non-demented
elderly people is recommended.References
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